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ABSTRACT
Phosphatidylinositols are membrane phospholipids that play an important role in the
regulation of vital functions in the cell. They are implicated in cell motitlity, cell
proliferation, programmed cell death, response to insulin and other hormones. However,
their interaction with the proteins they regulate is difficult to study due to their inclusion in
membranes. The present work propose the synthesis of a phosphatidylinositol 3,4-
bisphosphate analogue that will be covalently bond to the surface of PANAM dendrimers.
Due to the spherical micelle shape that these dendrimers possess it will be possible to
simulate the interaction between the lipids and a variety of proteins implicated in different
diseases like cancer and diabetes.
The preliminary steps in the synthesis of the a phosphatidylinositol 3,4-bisphosphate
analogue starting from a racemic mixture of the starting material 5,6-di-O-
cyclohexylidene-myo-inositol, are shown. The products have been purified by flash
chromatography and characterized by 1H NMR.
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1. INTRODUCTION
Membranes consisting of phospholipids bilayers are a ubiquitous component of all cells.
There are different kinds of phospholipids, depending on the characteristics of the head-
group, as well as the length, saturation, and branching of the hydrocarbon chains (Figure
1). Because of the different structures of lipids, the composition of biological membranes
is complex and variable, and depends both on the type of cell and the organelle of interest.
Some of the more abundant phospholipids include the neutral zwitterions
phophatidylcholine (PC) and phosphatidylethanolamine (PE), which constitute 60% of
total phospholipids in the inner leaflet. Additionally the negatively charged lipids
phosphatidylserine (PS) and phosphatidylinositol (PI) constitute 25% and 4% respectively.
PC is found both in the inner and the outer leaflet of plasma membrane bilayers, whereas
PS, PE and PI are located in the inner, cytosolic leafletxi.
Figure 1. Phospholipids found in cells membranes.
Mono- and polyphosphorylated derivatives of phosphatidylinositol, referred to as
phosphoinositides, for example phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2],
phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] and phosphatidylinositol 3,4-
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bisphosphate [PI(3,4)P2], represent <1% of total membrane phospholipids. They are
unique among phospholipids in their ability to be modified rapidly by
phosphorylation/dephosphorylation, to create (or eliminate) membrane-targeting signals at
particular locations. Two phosphoinositide-mediated signaling pathways have been
demonstrated, both of which originate from PI(4,5)P2, (Figure 2).
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Figure 2. Overview of the major roles of mono- and polyphosphorylated derivatives
of phosphatidylinositol in cellular signaling.
The first pathway involves the hydrolysis of PI(4,5)P2 by phosphatidylinositol-specific
phospholipase C (PLCg1) in response to agonist stimulations. This process produces two
signaling  molecules: diacylglycerol (DAG) and D-myo-inositol-1,4,5-trisphosphate
[I(1,4,5)P3]xii. DAG acts by stimulating protein kinase C, whereas I(1,4,5)P3 releases
calcium from internal sourcesxiii, mediating the effects of several neurotransmitters,
hormones and growth factors.
However, the activity of PLC-g on PI(4,5)P2 can be inhibited by the binding of the
cytoskeletal protein profilin to PI(4,5)P2xiv. In addition, this phosphoinositide-profilin
association can prevent the formation of profilactin (profilin-G-actin complex) which is
necessary in actin polymerization and cell motilityxv.
The second pathway that involves PI(4,5)P2 entails phosphoinositide 3-kinase (PI3K),
which is activated by growth factors, cytokines and insulin.  PI3K phosphorylates
PI(4,5)P2 at the D-3 position of the inositol ring, converting it into PI(3,4,5)P3. Proteins
that bind directly to PI(3,4,5)P3 are serine-threonine kinases Akt (also known as protein
kinase B, PKB) and phosphoinositide-dependent kinase 1 (PDK1)xvi. The binding of
PI(3,4,5)P3 to the membrane facilitates phosphorylation of Akt by PDK1, a process that
stimulates the catalytic activity of the former protein. Akt plays a key role in cancer
progression by stimulating cell proliferation and inhibiting apoptosis, and is also probably a
key mediator of insulin signalingxvii. The termination of PI3K signaling is obtained by 5-
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dephosphorylation of PI(3,4,5)P3 with Src-homology 2-containiing phosphatases (SHIP)6.
This produces PI(3,4)P2, an important phosphoinositide because it mediates PI3K-
dependent responses. Finally, the PI(3,4,5)P3 3-phosphatase (PTEN) dephosphorylates the
3 position of PI(3,4,5)P3 to produce PI(4,5)P2. Loss of PTEN has been found in a large
fraction of advanced human cancers, indicating that uncontrolled signaling through PI3K
contributes to metastatic cancersxviii.
Because of the role that phosphoinositides play in regulating the vital functions mentioned
(cell motitlity, cell proliferation, programmed cell death, response to insulin and other
hormones), the comprehension of the molecular basis of the interaction of these lipids with
the proteins they regulate is crucial to understand how the cell machinery works, and also
to obtain alternative ways to treat diseases as cancer and diabetes.
Domains that are known to recognize phosphoinositides include PH (pleckstrin
homology), PX (phox homology), FYVE, FERM, ANTH, ENTH domains and Tubby
proteinsxix,xx, (Figure 3). Recently, the generalities of the interactions found between these
domains and the phosphoinositides have been determined:
PI(3,4,5)P3 and PI(3,4)P2 targeted PH domains from such proteins as Akt (in the case of
PI(3,4,5)P3), are electrostatically polarized, with the positive charge in the
phosphoinositide binding site. These domains interact specifically and strongly with the
negative head-group of their phospholipid ligand. Similarly, PH domain of PLC-g binds to
PI(4,5)P2 electrostatically with short basic and polar residues. In addition, hydrophobic
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interactions can improve the membrane association. In the case of PX and FYVE domains,
they can recognize the lipid head-group of phosphatidylinositol 3-phosphate [PI(3)P]
specifically, but they don’t bind it with very high affinity. In order to increase their affinity,
these domains insert hydrophobic side-chains into the membrane bilayer or increase their
membrane-binding avidity through oligomerization. FERM domains of cytoskeletal
proteins, interact with PI(4,5)P2 lipids through regions that contain clusters of basic
residues and also hydrophobic interactions. ANTH and ENTH domains also interact with
PI(4,5)P2, but the latter induces curvature of its target membranes. Finally, Tubby proteins
have been found to bind to PI(4,5)P2, as well as PI(3,4,5)P3 and PI(3,4)P2, by electrostatic
interactions with their head-group.
Figure 3. Phosphoinositide recognition domains.
Therefore, it has been found that electrostatic interactions between a positive charge
located in phosphoinositide recognition domains, and the negative head-groups of these
PH  FYVE
PX ANTH
ENTH FERM Tubby
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lipids, are necessary upon binding. In addition, it has been proven that some of these
interactions occur by more than one binding site in the protein with different arrays of
lipids, suggesting that multivalency could be an important mechanism for specific protein-
lipid molecular recognition.
Although the improvements obtained in this field, it is still necessary to recognize the
details involved in these interactions in order to understand how the proteins mentioned
discriminate among the different kind of lipids during the processes they regulate.
Two of the reasons for which the insights of protein-lipid interactions are not well
understood involve the difficulties concerning the synthesis of lipids and their analogues
and the difficulty in studying protein-lipid interaction due to their inclusion in membranes.
Many proteins interact with phosphoinositides that are arranged in a specific array. Lipids
are able to diffuse in model membranes, therefore the spatial requirements for the
interaction are difficult to study.
In order to minimize these problems, the present project proposes the usage of a novel
class of lipid analogues that allow the display of multiple copies of the polar head-groups
on a spherical surface, to mimic the interaction of phosphoinositides with proteins. These
analogues are a derivatized form of polymers known as poliamidoamine dendrimers
(PAMAM™, Aldrich)xxi.
Dendrimers are characterized for being formed starting from initiator cores that posses Nc
reactive sites. These react with molecules possessing Nb reactive sites, which introduce
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multiplicity and produce what is known as dendrimers of generation 0. Repetition of this
sequence leads to generation 1, 2, 3, 4, etc. Each increase in integer value of the
generation number indicates a doubling in the number of termini on the surface of the
dendrimer. In the case of PAMAM dendrimers, NH2CH2CH2NH2 (Nc=3) can be used as
the initiator core and -CH2CH2CONHCH2CH2NH2 (Nb=2) as the repeating units (Scheme
1). PAMAM dendrimers increase their diameter by approximately 10 Å per generation,
evolving from a dislike shape (generations 0-2) to an oblate spheroid (generations 3,4) to
a symmetrical spheroid at generations 5 and higherxxii.
Scheme 1. Synthesis of PAMAM dendrimers starting from ethylene diamine,
NH2CH2CH2NH2.
PAMAM dendrimers (starting from generation 4) have been compared to micelle
systemsxxiii. They are similar in size and shape, and also simulate surface-group proximity
effects like the ones found in spherical micelles and also in liposomes or bilayers.
However, these polymers have the advantage that the head-group multiplicity is
determined by synthesis, whereas in self-adjusting micelle systems the head-groups are
determined by free-energy minimization.
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The surface head-groups of PAMAM dendrimers can be derivatized and this property will
be used to obtain dendrimers mimicking phosphoinositide lipid head-groups.
Among the phosphoinositides analogues of interest, it is the PI(3,4)P2 analogue. The goal
of the current research work will be the production of the PI(3,4)P2 analogue by an
appropriate derivatization of a PANAM dendrimer.
The chiral starting material necessary for the synthesis was prepared by Nichole Stewart at
the Oakley laboratory. Firstly, the (±)-6-O-Butyril-1,2,4,5-di-O-cyclohexylidene-myo-
inositol was obtained protecting inositol in the 1, 2, 4 and 5 positionsxxiv, following by its
esterification at position 6 (Scheme 2).
Scheme 2. Obtainment of (±)-6-O-Butyril-1,2,4,5-di-O-cyclohexylidene-myo-inositol.
The butyril ester of the racemic mixture (±)-1, was subjected to enantioselective hydrolysis
by porcine pancreatic lipase applying the procedure developed by Chen and co-workers13,
Scheme 3.
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Scheme 3. Kinetic resolution of butyryl ester using porcine pancreatic lipase.
In Scheme 3 is also shown that the (+)-1 enantiomer is the precursor of the PI(4,5)P2
analogue that Sarah Webb synthetized at the Oakley laboatory. From the kinetic
resolution, the (-)-1 enantiomer, which is the precursor for the PI(3,4)P2 analogue, was
also obtained. Because the enantiomeric material is very valuable, the current research will
convert the racemic mixture into the PI(3,4)P2 analogue as a preliminary step.
After obtaining the PI(3,4)P2 head-group analogue, it will be reacted with the vinilogous
amide ester dendrimer of choice using the reaction sequence that follows (Scheme 4).
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Scheme 4. Synthesis of PI(3,4)P2 micelle mimic.
The reaction sequence shown (Scheme 4) was used and optimized by Sarah Webb to
obtain the PI(4,5)P2 analogue as part of her research work to pursue the degree of Doctor
in Philosophyxxv.
The tetherable head-group was proposed to be prepared using the synthetic routexxvi
shown in Scheme 5.
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Scheme 5. Synthetic route of PI(3,4)P2 analogue.
At the time this document was written compounds 2, 3, and 4 were synthesized. The
mechanistic insights and experimental discussion will be focus on the synthesis of these
molecules.
The obtainment of the racemic mixture of 3,4-di-O-allyl-1,2,5,6-di-O-cyclohexylidene-
myo-inositol, compound 2, involves a SN2 reaction type. The nucleophile is obtained by
dehydrogenation of the OH groups with NaH as the base. Compound 2 is produced when
the strong electrophile allyl bromide is attacked by this nucleophile.
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Scheme 6. Mechanism of the synthesis of 3,4-di-O-allyl-1,2,5,6-di-O-cyclohexylidene-
myo-inositol (2).
Compound 3, the racemic mixture of 3,4-di-O-allyl-1,2-O-cyclohexylidene-myo-inositol,
is obtained by catalytic acidic deprotection of the alcohol groups as shown in Scheme 7.
The acidic media necessary for the reaction is produced catalytically by reaction of
methanol with acetyl chloride. Triethylamine is used to quench the acidic mixture at the
end of the reaction.
Scheme 7. Mechanism of the synthesis of 3,4-di-O-allyl-1,2-O-cyclohexylidene-myo-
inositol (3).
Similarly to the obtainment of compound 2, the racemic mixture of 3,4-di-O-allyl-5,6-di-
O-benzyl-1,2-di-O-cyclohexylidene-myo-inositol, compound 4, is obtained using NaH to
generate the nucleophile which can attack the reactive benzyl bromide.
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Scheme 8. Mechanism of the synthesis of 3,4-di-O-allyl-5,6-di-O-benzyl-1,2-di-O-
cyclohexylidene-myo-inositol (4).
2. MATERIALS AND METHODS
All reagents were purchased from Sigma-Aldrich.
The reactions were followed by thin layer chromatography (TLC) using silica gel 60 F254.
Silica gel (Whatman-Fisher) for flash chromatography was 230-400 mesh (60 Å).
NMR spectra were collected using either a 300 (1H) or 400 (1H) MHz Varian Inova NMR
spectrometer.
2.1. Synthesis of 3,4-di-O-allyl-1,2,5,6-di-O-cyclohexylidene-myo-inositol (2)
A solution of the racemic mixture 1 (0.5 g, 1.47 mmol) in N,N-dimethylformamide,
(DMF) (3 mL) was treated with NaH 60% (0.352 g, 8.8mmol, 6 equiv.) in an ice bath (-
72°C). The mixture was stirred for 15 min. Allyl bromide (0.45 mL, 5.13 mmol, 3.5
equiv.) was added at room temperature and the reaction was stirred under Ar atmosphere
for 4 h. The excess of NaH was destroyed with methanol 0 °C. CH2Cl2 was added and the
solution was washed with water and NaCl(sat). The organic layer was dried with MgSO4,
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and concentrated under reduced pressure. Column chromatography (hexanes:ethyl acetate,
10:0.85) of the residue gave 0.5 g of 3,4-di-O-allyl-1,2-O-cyclohexylidene-myo-inositol
(80 % yield).
1H-NMR in CHCl3-d1, d (ppm): 1.37-1.72 (m, 20 H, 10 CH2); 3.42 (dd, 1 H, CH);
3.63 (t, 1 H, CH); 3.75 (dd, 1 H, CH); 4.04-4.2 (m,
5 H, CH and 2 OCH2); 4.29 (m, 1 H, CH); 4.35 (m,
1 H, CH); 5.14-5.18 (m, 2 H, CH2=C); 5.25-5.32
(m, 2 H, CH2=C); 5.84-5.95 (m, 2 H, 2 C=CH).
2.2. Synthesis of 3,4-di-O-allyl-1,2-O-cyclohexylidene-myo-inositol (3)
A solution of 3,4-di-O-allyl-1,2-O-cyclohexylidene-myo-inositol (0.05 g, 0.118 mmol) in
CH2Cl2-CH3OH (1:1, 1.4 mL) was stirred with acetyl chloride (0.0015 mL, 0.0213 mmol,
0.18 equiv.) at room temperature for 55 min. Triethylamine (0.049 mL, 0.335 mmol, 3
equiv.) was added and the solution was concentrated under reduced pressure. Column
chromatography (hexanes:ethyl acetate, 0.8:1) of the residue gave 0.032 g of 3,4-di-O-
allyl-1,2-O-cyclohexylidene-myo-inositol (80 % yield).
1H-NMR in CHCl3-d1, d (ppm): 1.22-1.75 (m, 10 H, 5 CH2); 2.86 (s, 2 H, OH);
3.24-3.32 (m, 1 H, CH); 3.55-3.6 (m, 2 H, CH);
3.71 (dd, 1 H, CH); 3.966 (dd, 1 H, CH); 4.18-4.22
(m, 3 H, CH and OCH2); 4.37-4.43 (m, 2 H,
OCH2); 5.14-5.19 (m, 2 H, CH2=C); 5.25-5.31 (m,
2 H, CH2=C); 5.86-6.0 (m, 2 H, 2 C=CH).
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2.3. Synthesis of 3,4-di-O-allyl-5,6-di-O-benzyl-1,2-di-O-cyclohexylidene-myo-
inositol (4)
A solution of 3,4-di-O-allyl-1,2-O-cyclohexylidene-myo-inositol (0.088 g, 0.258 mmol) in
N,N-dimethylformamide (0.89 mL) was treated with NaH 60 % (0.062 g, 1.55 mmol, 6
equiv.) in an ice bath (-72°C). The mixture was stirred for 15 min. Benzyl bromide (0.109
mL, 0.904 mmol, 3.5 equiv.) was added at room temperature and the reaction was stirred
under Ar atmosphere for 4 h. The excess of NaH was destroyed with methanol at 0 °C.
CH2Cl2 was added and the solution was washed with water and NaCl(sat). The organic layer
was dried with MgSO4, and concentrated under reduced pressure. Column
chromatography (hexanes:ethyl acetate, 5:0.8) of the residue gave 0.113 g of 3,4-di-O-
allyl-5,6-di-O-benzyl-1,2-di-O-cyclohexylidene-myo-inositol (89% yield).
1H-NMR in CHCl3-d1, d (ppm): 1.1.58-1.71 (m, 10 H, 5 CH2); 3.36 (dd, 1 H, CH);
3.58 (dd, 1 H, CH); 3.75 (dd, 2 H, CH); 4.14 (dd, 1
H, CH); 4.19-4.3 (m, 4 H, 2 OCH2); 4.33-4.37 (m,
1 H, CH); 4.71-4.89 (m, 4 H, 2 OCH2C6H5); 5.13-
5.19 (m, 2 H, CH2=C); 5.25-5.32 (m, 2 H, CH2=C);
5.92-5.99 (m, 2 H, 2 C=CH); 7.23-7.35 (m, 10 H, 2
C6H5).
3. RESULTS AND DISCUSSION
There were not major complications in the obtainment of compounds 2, 3 and 4. These
were obtained pure as their proton magnetic resonance spectra (1H-NMR) revealed.
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1H-NMR spectrum of compound 2, (Figure 4) does not show the OH peak located at
2.59 ppm in the 1H-NMR spectrum of the starting diol (Figure 5). However, compound 2
does have peaks located around 5.9 ppm which are not in the starting diol, and that
correspond to hydrogens of C=CH functional group. These peaks together with the ones
between 5.14 and 5.32 ppm revealed that the starting material was successfully allylated.
Figure 4. . 1H-NMR in CHCl3-d1 of  3,4-di-O-allyl-1,2,5,6-di-O-cyclohexylidene-myo-
inositol (compound 2).
Figure 5. 1H-NMR in CHCl3-d1 of starting diol (±)-1
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1H-NMR spectrum of compound 3 (Figure 6) shows a broad peak located at 2.86 ppm
that corresponds to the OH groups of the deprotected molecule. In this spectrum it can
also be seen that the intensity of the peaks located between 1.22 and 1.75 ppm are half
the intensity of the similar peaks shown in the 1H-NMR spectrum of compound 2 (Figure
4). These characteristics confirmed the obtainment of compound 3.
Figure 6. 1H-NMR in CHCl3-d1 of 3,4-di-O-allyl-1,2-O-cyclohexylidene-myo-inositol
(compound 3).
Figure 7. 1H-NMR in CHCl3-d1 of  3,4-di-O-allyl-5,6-di-O-benzyl-1,2-di-O-
cyclohexylidene-myo-inositol (compound 4).
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Finally, the obtainment of compound 4 could be confirmed because its 1H-NMR spectrum
(Figure 7) did not show the peak corresponding to the OH groups that can be found in
the spectrum of compound 3 (Figure 6), and also because it shows a multiplet at 7.23-
7.35 ppm that correspond to phenyl hydrogens.
One of the main purposes of this work was to optimize the percentage yields of the
reactions mentioned. Table 1 shows a summary of the reactions carried out.
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Table 1. Percentage yields achieved in the obtainment of compounds 2, 3 and 4.
Synthesis of compound 2
Starting Material (g) Product (g) % yield
0.1 0.048 40
0.5 0.158 26
0.5 0.37 65
Starting diol (+/-)-1
0.5 0.5 80
Synthesis of compound 3
Starting Material (g) Product (g) % yield
0.05 0.0145 37
0.05 0.0323 80
0.2 0.0889 56
Compound 2
0.34 0.16 60
Synthesis of compound 4
Starting Material (g) Product (g) % yield
0.088 0.113 89
Compound 3
0.192
Noah Benjamin pg 70 0.32
0.39 61
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Synthesis of compound 2 was done without major complications. The use of 6 equivalents
of NaH was found to be necessary to obtain a better yield. The first two low percentages
yields shown corresponds to spills during the work up of the reaction mixture, and
problems during the purification of the product like the use of an unnecessary amount of
silica.
Compound 3 was more difficult to obtain in good yields. The 4,5-cyclohexylidene is more
susceptible to be deprotected by this method because of the conformational strain present
in the 4,5 trans acetal. However, 1,2-cyclohexylidene group can also be deprotected but at
a slower rate. In order to improve the yield, the reaction was carefully monitored by thin
layer chromatography (TLC) and stopped when the fully deprotected product started to
form. Distillation of the methanol and methylene chloride mixture prior the reaction could
improve the yield. The presence of water could produce larger amounts of acidic protons,
and consequently, it could allow the deprotection of the 1,2-cyclohexylidene group.
Compound 4 was obtained in good yield. 6 equivalents of NaH were also necessary to
carry out the synthesis. 61% yield corresponds to the synthesis using not only compound 3
but also a significant amount of 3,4-di-O-allyl-6-O-benzyl-1,2-O-cyclohexylidene-myo-
inosoitol produced by Noah Benjamin at the Oakley laboratory. Some fractions collected
during the column chromatography, besides the ones that contained the pure product,
revealed its presence among the fractions, suggesting that the percentage yield could have
been greater.
4. CONCLUSIONS
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Racemic mixture of 3,4-di-O-allyl-1,2,5,6-di-O-cyclohexylidene-myo-inositol, 3,4-di-O-
allyl-1,2-O-cyclohexylidene-myo-inositol, and 3,4-di-O-allyl-5,6-di-O-benzyl-1,2-di-O-
cyclohexylidene-myo-inositol were successfully obtained in good yields using the synthetic
route proposed. These products were purified by flash chromatography and theirs
structures identified by proton magnetic resonance spectrometry (1H-NMR).
5.  FUTURE WORK
In the near future, a bigger amount of each of the products already synthesized will be
produced in order to continue with the rest of the steps specified in Scheme 5. All the
products will be purified and characterized. Once each step have been improved to give a
good yield the PI(3,4)P2 analogue will be synthesize using the (-)-1 enantiomer from
Scheme 3, and the surface of a PANAM dendrimer will be derivitized with it.
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